Estimating the potential impact and diagnostic requirements for SARS-CoV-2 test-and-treat programs

Mostrar otras versiones (1)

Oral antivirals have the potential to reduce the public health burden of COVID-19. However, now that we have exited the emergency phase of the COVID-19 pandemic, declining SARS-CoV-2 clinical testing rates (average testing rates = ≪10 tests/100,000 people/day in low- and-middle income countries; <...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Alvin X., Hannay, Emma, Carmona, Sergio, Rodriguez, Bill, Nichols, Brooke E., Russell, Colin A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558441/
https://www.ncbi.nlm.nih.gov/pubmed/36238715
http://dx.doi.org/10.1101/2022.10.05.22280727

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558441/
https://www.ncbi.nlm.nih.gov/pubmed/36238715
http://dx.doi.org/10.1101/2022.10.05.22280727

Ejemplares similares